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Background: Non-typeable Haemophilus influenzae (NTHi) is a Gram negative microorganism residing in the human
nasopharyngeal mucosa and occasionally causing infections of both middle ear and lower respiratory airways. A
broadly protective vaccine against NTHi has been a long-unmet medical need, as the high genetic variability of
this bacterium has posed great challenges.
Results: In this study, we developed a robust serum bactericidal assay (SBA) to optimize the selection of protective
antigens against NTHi. SBA takes advantage of the complement-mediated lysis of bacterial cells and is a key in vitro
method for measuring the functional activity of antibodies. As a proof of concept, we assessed the bactericidal activity
of antibodies directed against antigens known to elicit a protective response, including protein D used as carrier protein
in the Synflorix pneumococcal polysaccharide conjugate vaccine. Prior to SBA screening, the accessibility of antigens to
antibodies and the capacity of the latter to induce C3 complement deposition was verified by flow cytometry. Using baby
rabbit serum as a source of complement, the proposed assay not only confirmed the bactericidal activity of the antibodies
against the selected vaccine candidates, but also showed a significant reproducibility.
Conclusions: Considering the rapidity and cost-effectiveness of this novel SBA protocol, we conclude that it is likely to
become an important tool to prove the capability of antibodies directed against recombinant antigens to induce NTHi
in vitro killing and to both select new protective vaccine candidates, and predict vaccine efficacy.
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Non-typeable Haemophilus influenzae (NTHi) is a Gram
negative microorganism that differs from the other Hi
serotypes for the lack of a polysaccharide capsule. NTHi
is a commensal in the human nasopharyngeal mucosa
and may occasionally act as a pathogen initiating infec-
tions of both the upper and lower respiratory airways,
causing conditions such as otitis media (OM), chronic
obstructive pulmonary disease (COPD), and invasive dis-
eases such as meningitis and sepsis, especially in neo-
nates and the elderly [1-3].* Correspondence: marco.x.soriani@gsk.com; silvia.x.rossi-paccani@gsk.com
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unless otherwise stated.A broadly protective vaccine against NTHi is a current
medical need. Indeed, one of the major hurdles to NTHi
vaccine development is the high genetic diversity among
strains, leading to the necessity to identify antigens car-
rying functional epitopes able to induce cross-protective
antibodies [4].
As NTHi does not express a capsule, the search for al-
ternative vaccine candidates has so far been focused on
outer membrane proteins and lipo-oligosaccharide [5]. A
protective antigen should express epitopes available for
antibody binding on the surface of the intact bacterium.
Molecules embedded within the outer membrane or
blocked by steric hindrance of adjacent structures, such
as sialic acid could be unavailable for antibody binding
and therefore unable to generate protective antibodies.
Currently, major (P1, P2, P4, P5) and minor (P6, D15,his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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(HMW, Hia, pili, P5) are being studied, and preclinical
results including the use of animal models have been
generated. In particular, protective efficacy of PD, OMP26
and P5 was proved using models of otitis (chinchilla model
of otitis media) and lung infection (rat model of pulmonary
clearance) [6-8]. This approach provided important infor-
mation on the impact of the host-pathogen relationship on
whole tissue, and the interaction between humoral and cel-
lular response. However, these experiments are very expen-
sive, and consequently limit the possibility to screen for
strains with different genetic background.
A well-established in vitro method to predict antigen pro-
tective ability is the Serum Bactericidal Assay (SBA). The
SBA is also referred to as complement-mediated bacterial
killing and quantifies bacterial cell death after incubation
of bacterial cells with immune serum and a complement
source. In particular for Neisseria meningitidis, SBA activity
has been shown to highly correlate with immunity to
meningococcal disease [9-11] and more recently Borrow’s
group has evaluated and validated a novel SBA for Hae-
mophilus influenzae type B [12]. However, SBA was never
established for NTHi due to the high susceptibility of this
non-encapsulated microorganism to complement-mediated
killing. In this study, we modified and optimized SBA to
evaluate the functional activity of antibodies generated fol-
lowing mice immunization with a panel of recombinant
NTHi antigens already reported to have protective capabil-
ity in animal models. This assay could constitute a rapid
and low cost tool for antigen selection.
Results and discussion
Selection of the antigens to develop a Serum Bactericidal
Assay for NTHi
The aim of this study was to set up a robust assay to
screen the antigens capable of raising functional anti-
bodies to kill NTHi. First of all, we selected from the lit-
erature a panel of proteins already reported to be
protective in animal models (Protein E [13], Protein D
[14], P6 [15], OMP26 [16], PilA and HtrA [17]). This
helped us to set the best working conditions of the assay.
Moreover, we used an unrelated protein (that is not
present on NTHi surface) as negative control. We selected
NHBA from N.meningitidis as unrelated protein-it is a
surface protein that is strictly specific for meningococcus.
Surface accessibility of NTHi antigens
Since the prerequisite for the functionality of the assay is
that the antigen tested should be exposed on the bacter-
ial surface, we verified the surface exposure of the se-
lected antigens. First of all the antigens were formulated
with AL(OH)3 as an adjuvant, and immunized in mice,
after which polyclonal antibodies were obtained. As
shown in Figure 1, all the antigens tested (PD, PE, P6,OMP26, HtrA and PilA) were well exposed on the sur-
face of live bacteria.
Selection of a complement source
Selection of a suitable source of complement repre-
sented a crucial step in setting up a SBA. Several lots of
sera derived from baby rabbit and guinea pigs were
screened to evaluate toxicity. Briefly, 176 strain was in-
cubated for 60 min with different concentration (12.5%,
25% 50%) of baby rabbit or guinea pig complement.
Bacteria without complement and bacteria with heat-
inactivated complement (dilution factor = 50%) were
used as control. The mixture was then plated on agar
chocolate plates to evaluate NTHi strain survival. We
discarded sera which resulted to be toxic for NTHi, and
identified Baby Rabbit serum (lot 7504) as good comple-
ment source for the assay (Figure 2). We assumed that a
serum was not toxic at the dilution used in the SBA (25%),
when the number of bacteria at T60min was more than
double the number of targets cells present before the incu-
bation with complement.
Evaluation of C3 complement deposition
We next assessed the ability of the specific sera to in-
duce complement deposition on NTHi surface. Using
flow cytometry analysis, we therefore evaluated if spe-
cific antibodies against NTHi antigens were able to pro-
mote C3 deposition, a crucial step in complement
pathway cascade. Basically, bacteria in exponential phase
were incubated with rabbit complement in the absence
or presence of increasing amounts of sera from mice im-
munized with NTHi antigens (Figure 3, lower panel) or
176 strain heat inactivated (Figure 3, upper panel). C3
deposition was detected using anti-rabbit C3 antibody
and anti-Rabbit Secondary Antibody, Alexa Fluor® 488
conjugate. As reported in Figure 3, anti-176 as well as
anti-PilA, anti-PD and anti-PE antibodies were able to
promote C3 component deposition on bacterial surface
leading to activation of complement pathway. Serum
form mice given alum was used as negative control.
Development of a reproducible serum bactericidal assay
The functionality of the antibodies raised against 176
strain or against specific NTHi antigens was assessed by
SBA. To perform the SBA, bacteria in exponential phase
were incubated with complement in the absence or pres-
ence of increasing amounts of sera from mice immunized
with selected antigens. To validate the assay, we evaluated
bactericidal activity of antibodies directed against antigens
proved to be protective in in vivo models of colonization
and infection, such as Protein E [13], Protein D [14], P6
[15], OMP26 [16] and HtrA [17]. As postulated, sera raised
against PD, PE, P6, OMP26, HtrA and PilA antigens were
able to induce in vitro killing of 176 strain, consistently with
Figure 1 NTHi antigens are accessible to antibodies on bacterial surface. Binding of anti-PD, PE, P6, OMP26, HtrA, PilA and anti-176 to live bacteria
was evaluated by flow cytometry. Histograms represent a typical experiment out of two performed with similar results. RFI, relative fluorescence
intensity. Filled gray line, bacteria incubated with an irrelevant serum; red line, bacteria incubated with antigen specific serum.
Ercoli et al. BMC Microbiology  (2015) 15:87 Page 3 of 8their capacity to promote complement deposition. SBA ti-
ters obtained vary from protein to protein and it is due to
several factors, including antigen density and antibody af-
finity. Notably, SBA titers well correlated with surface ex-
pression of antigens (Figure 1). In particular, PD and HtrA
that appeared to be more accessible to antibodies on the
bacterial surface, were among the antigens giving higher
SBA titers (Table 1). Sera from a) non-immunized mice
(pre-immune sera); b) mice immunized with PBS alone; c)
mice immunized with adjuvant alone (AL(OH)3); d) mice
immunized with an adjuvanted unrelated antigen (NHBA
from N. meningitidis) were used as negative controls. None
of these sera induced detectable SBA titers (Table 1).
Furthermore, given the extensive genetic diversity exhib-
ited by NTHi we validated the bactericidal assay with
genetically diverse strains belonging to different clades
identified by genome-based population structure of NTHi[4]. Preliminary data show that the assay is applicable also
to strains genetically different (data not shown).
Conclusions
Reverse Vaccinology and other profile-based computational
approaches [18] allow the identification of a large number
of open reading frame encoding for surface proteins, how-
ever the subsequent screening for bactericidal epitopes is a
clear bottleneck. In vitro SBA has been proved to be a rapid
and cost-effective method to identify new vaccine candi-
dates and, as in the case of the Type B meningococcus vac-
cine, a valid correlate of protection [9-11]. A high genetic
diversity not correlating with disease is an important signa-
ture of NTHi species and represents a crucial issue in the
development of a successful vaccine against this human
pathogen. Selection of protective antigens should therefore
consider this aspect by supporting the prioritization of
Figure 2 Selection of complement source. 176 strain was tested for survival at different baby rabbit or guinea pig serum concentrations (12.5%, 25%,
50%) for 60 min. Bacteria without complement and bacteria with heat-inactivated complement (dilution factor 50%) were used as negative control.
The results are expressed as % survival at 60 min. The means and standard errors from 3 independent experiments are shown. Error bars represent the SD.
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cross-protective antibodies. In this study, we propose a
novel SBA for NTHi that would help to identify
broadly-protective vaccine candidates through a rapid
screening of both antigens and strains.Figure 3 Sera against specific antigens promote C3 fragment deposition on N
presence of increasing amounts of sera from mice immunized with NTHi antige
(mean fluorescence) was measured by flow cytometry. Serum form mice
one representative experiment for anti-176 serum are shown in additionMethods
Antibodies and reagents
Antibody against C3 complement component was from
Calbiochem. Goat anti-Mouse IgG (H + L) Secondary Anti-
body, Alexa Fluor® 488 conjugate, and Goat anti-Rabbit IgGTHi. 176 strain was incubated with rabbit complement in the absence or
ns or 176 strain heat inactivated. The amount of C3 deposited on bacteria
given alum was used as negative control. Histogram tracings from
to three of the antigens analyzed. RFI, relative fluorescence intensity.
Table 1 Bactericidal activity against 176 strain
Sera SBA titers
α-PilA-AL(OH)3 341 ± 147
α-HtrA-AL(OH)3 853 ± 295
α-PE-AL(OH)3 512
α-OMP26-AL(OH)3 192 ± 90
α-PD-AL(OH)3 853 ± 295






Bactericidal titers obtained using sera against specific antigens are reported.
Titers are expressed as the reciprocal of the serum dilution necessary to
obtain >50% bacterial killing. Experiments were performed three times and average
titers is reported. Serum against NTHi was used as positive control. Sera
from non-immunized mice (pre-immune sera), mice immunized with PBS
alone, mice immunized with adjuvant alone (AL(OH)3), mice immunized with
an adjuvanted unrelated antigen (NHBA from N. meningitidis) were used as
negative controls. Data are means and standard errors of the means from 3
separate experiments.
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were from Molecular Probes.
Baby rabbit complement and Guinea Pig complement
were from Cederlane Labs. AL(OH)3 was purchased
from Sigma-Aldrich.
Bacterial strains and growth conditions
NTHi strain 176 (kindly provided by Richard Moxon
and Derek Hood, Oxford University, UK), isolated from
a child with otitis media, was used for this study. NTHi
was grown on chocolate agar polivitex (BioMerieux) at
37°C with 5% CO2. Brain-heart infusion (BHI) broth
(Difco Laboratories) supplemented with 10 μg/mL each
of haemin (Fluka Biochemika) and nicotinamide adenine
dinucleotide (NAD, Sigma) was used as fluid growth
medium. Escherichia coli strains DH5α, HK100 and
BL21 (DE3) (Invitrogen) were used for cloning and ex-
pression of NTHi antigens. They were cultured at 37°C
in Luria Bertani (LB) medium and, when required, sup-
plemented with 100 μg/mL ampicillin.
Cloning of genes coding for vaccine antigens
NTHi genes were cloned into the pET15b + vector
(Novagen) using the polymerase incomplete primer ex-
tension (PIPE) method [19]. Sequences coding for each
protein were amplified by PCR from the 176 genomic
DNA, removing the signal peptide (primers are listed in
Additional file 1: Table S1 in the supplemental mater-
ial). PCRs generated mixtures of incomplete extension
products; short overlapping sequences were introduced
at the ends of these incomplete extension mixtures,which allowed complementary strands to anneal and
produce hybrid vector-insert combinations. Escherichia
coli HK100 cells [20] were then transformed with
vector-insert hybrids. Single ampicillin-resistant colonies
were selected and checked for the presence of the recom-
binant plasmid by PCR. Plasmids from positive clones were
isolated and subcloned into competent E. coli BL21(DE3)
cells.
Antigen expression, purification and formulation
For protein expression and purification, one single colony
of E. coli BL21(DE3) strain expressing NTHI antigens was
inoculated in LB plus ampicillin and grown overnight at
37°C, diluted in fresh LB medium and grown at 30°C to an
OD600 of 0.6-0.8. Protein over-expression was induced by
the addition of 1 mM isopropyl-1-thio-β-D-galactopyrano-
side (IPTG, Sigma) for 3 hours. Recombinant 6 x His-
fusion proteins was purified by affinity chromatography
on Ni2+-conjugated chelating fast-flow Sepharose 4B resin
(Pharmacia). Purity was checked by SDS-PAGE electro-
phoresis staining with Coomassie blue. Protein concentra-
tion was determined using the bicinchoninic acid (BCA)
assay (Thermo Scientific). Endotoxin content was assessed
using the limulus amoebocyte lysis (LAL) test.
Antigens were adsorbed onto alum by incubating 10 μg
of each antigen with 2 mg/ml aluminum hydroxide, with
slow stirring for few hours at room temperature (RT). The
pH and osmolality of the formulation and antigen absorp-
tion were determined.
Polyclonal antisera production
In order to produce polyclonal antisera, groups of eight
CD1 mice were immunized with 10 μg of each purified
Ag adsorbed onto aluminum hydroxide. The recombin-
ant protein was given intraperitoneally on day1. Booster
doses were administered on day 21 and 35. Blood sam-
ples were taken on day 49. To generate anti-NTHi anti-
bodies, mice were injected with heat inactivated bacteria
(108 cfu in each dose) following the same administration
and sampling route. Control mice received equal amounts
of saline or alum or adjuvanted unrelated antigen. All treat-
ments were performed in accordance with internal animal
ethical committee and institutional guidelines.
Complement toxicity assay
Toxicity assay was performed in order to screen the best
source of complement to use in the SBA. A panel of
baby rabbit and guinea pig sera was tested to evaluate
toxicity against NTHi. In particular, serially diluted baby
rabbit or guinea pig sera were incubated with mid-log
phase bacteria for 1 h at 37°C and the survival rate was
calculated for each dilution by CFU counting. The selec-
tion of the ideal source of complement was based on
two main criteria: the serum should show an activity
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toxic for NTHi. We assumed that a serum was not toxic
when the number of bacteria at T1hour was more than
double the number of target cells present before comple-
ment incubation. Heat inactivated sera were used as
negative control.Flow cytometry analysis
Surface exposure of NTHi antigens was assessed by in-
cubating bacteria in exponential phase with sera derived
from mice immunized with recombinant proteins for
30 min at 4°C. After washing, cells were stained with
anti-Mouse Secondary Antibody, Alexa Fluor® 488 con-
jugate. Cells were analyzed with a Canto II flow cyt-
ometer (Beckton-Dickinson) using Flowjo software. The
geometric mean fluorescence intensity (MFI) for each
population was calculated.
To assess C3 complement component deposition, bac-
teria in exponential phase were incubated with 25% baby
rabbit serum, as a source of complement, plus serial di-
lution of specific polyclonal anti-sera for 20′ at 37°C,
180 rpm. The capacity of specific sera to promote C3
deposition was revealed using anti-rabbit C3 antibody
and anti-Rabbit Secondary Antibody, Alexa Fluor® 488
conjugate. Cells were analyzed with a Canto II flow cyt-
ometer (Beckton-Dickinson) by using Flowjo software.Figure 4 NTHi SBA protocol. Bacteria are diluted in Dulbecco’s PBS contain
with baby rabbit complement (B), and serially diluted sera raised against th
assay is shown in panel (D).The geometric mean fluorescence intensity (MFI) for
each population was calculated.
Serum bactericidal assay (SBA)
Non-typeable Haemophilus influenzae target strain lysis
was assessed in the presence of NTHi-specific antibody
and complement (antibody mediated, complement-
dependent killing). Antisera were tested in a serum
bactericidal assay to verify their capacity to induce
NTHi in vitro killing. Sera from non-immunized mice
(pre-immune sera), mice immunized with PBS alone,
mice immunized with adjuvant alone (AL(OH)3) and
mice immunized with an adjuvanted unrelated antigen
(NHBA from N. meningitidis) were used as negative
controls.
Bacteria were subcultured on chocolate round agar
plates and incubated ca. 18 hours at 37°C, 5% CO2. Col-
onies were inoculated in 4 ml of BHI plus hemin (10 μg/
ml) and NAD (10 μg/ml) and incubated on a shaker at
37°C with 5% CO2 180 rpm until OD600 = 0.5 (6x10
8
CFU/ml). Bacteria were centrifuged for 10 minutes,
2000 x g, at room temperature. Supernatants were dis-
carded and the pellet was resuspended in Dulbecco’s
PBS containing 1% (w/v) BSA and 0.1% (w/v) glucose
(assay buffer). A working dilution of bacteria was made
in the assay buffer (1:50000). Serial 2-fold dilutions of sera
(previously heat inactivated 30′ 56°C) were prepared bying 1% (w/v) BSA and 0.1% (w/v) glucose (A); they are then incubated
e selected antigens (C). The microtiter plate layout for the NTHi SBA
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to 25 μl of assay buffer previously added to the wells, mix-
ing, and then transferring 25 μl into the next well (the pro-
cedure was repeated from column 2 to 10) (Figure 4C).
The assay was performed in sterile 96-well plates in a
final volume of 50 μl per well, as represented in Figure 4D.
Bacteria working dilution was added to each well (12.5 μl
corresponding to 200 cfu). Then 12.5 μl of active com-
plement were added to the wells in Columns 1 to 11,
while heat inactivated complement was added in column
12 (Figure 4D). Indeed, two internal controls were intro-
duced in the assay: a Complement Dependent Control, to
measure the killing induced by the complement per se in
absence of antibodies (column 11, Figure 4D) and a Com-
plement Independent Control, to measure the killing in-
duced by serum alone in presence of heat inactivated
complement (column 12, Figure 4D).
Bacteria at time zero (T0) were plated in duplicate.
The plate was incubated for 1 h at 37°C with 5% (v/v)
CO2 in a humidified atmosphere and on a soft orbital
rotating shaker. Bacteria at T60min were sampled, and
spotted onto agar plates (all wells were plated in dupli-
cate). Agar plates were incubated overnight at 37°C in a
humidified atmosphere with 5% (v/v) CO2. On the fol-
lowing day, colony forming units (cfu) were counted for
T0 and T60min in order to evaluate the bactericidal titer
of each serum. The number of colonies in column 11 is
the number of viable cells. We assumed that a serum di-
lution has bactericidal activity when after 1 h of incuba-
tion at 37°C, more than 50% of the bacteria were killed
with respect to T0. The bactericidal antibody titer was
expressed as the reciprocal of the final serum dilution
yielding ≥50% killing at T60min as compared with the
average for control wells (T0).Additional file
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